Acomplia — manufactured by Sanofi-Aventis — is proving effective and safe in weight loss treatment. In a recent study, it reported that 39% of patients, after the first year of treatment, taking high-dose Acomplia were able to reach a goal of losing 10% of their weight. And after two years, 32% of the high-dose patients maintained that level of weight loss.

Acomplia (Rimonabant) is an innovative appetite suppressant medication that is able to block your hunger receptors. It works by allowing your cardio-metabolic system to function well. The direct association of this drug is with the CB1 factor in the human brain that plays a vital role in determining the body weight. Once a control over this CB1 factor is achieved you can easily regulate the weight.

Moreover, this promising drug is also a new tool which helps to quit smocking and increase the “good cholesterol (HDL)”. "The results are very encouraging," said Sidney C. Smith Jr., a University of North Carolina cardiologist who had no role in the study. On the contrary, the two-year study also showed some side effects depression, anxiety, irritability which did not last long.

However, Van Gaal— who is a professor of diabetology, metabolism, and clinical nutrition at the University of Antwerp in Belgium — says, because "people always say they want to lose 40 pounds, but you can achieve real health benefits by losing 10% of your body weight. This is a realistic and sustainable goal." He says other studies have reported that patients who hit the 10% goal cut their risk of developing diabetes in half.

The other encouraging thing is that it is also efficient in preventing heart or circulatory disorders like high blood pressure. But, it works better and faster if the drug is consumed by maintaining a proper fitness schedule — exercise and diet plan.

So, this reveals a rich data about Acomplia - that shows it is quite helpful in reducing extra pounds and as well as maintaining that weight loss. But, the last best thing Sanofi-Aventis is waiting for - is the approval from FDA.